The daily subcutaneous injection of sulpiride produced increase tumor growth and decrease of survival in DBA/2 mice bearing a transplanted mammary gland tumor. It is proposed that sulpiride effect may be mediated by the augment of prolactin level in serum.
Get full access to this article
View all access options for this article.
References
1.
BootL. M.: A review: Prolactin and mammary carcinogenesis. The problem of human prolactin.Int. J. Cancer, 5: 167–175, 1970.
2.
DebeljukL., RozadosR., DaskalH., Villegas VelezC., ManciniA. M.: Acute and chronic effects of sulpiride on serum prolactin and gonadotropin levels in castrated male rats.Proc. Soc. Exp. Biol. Med., 148: 550–552, 1975.
3.
MeitesJ.: Relation of prolactin and estrogen to mammary tumorigenesis in the rat.J. Natl. Cancer Inst., 48: 1217–1224, 1972.
4.
SekiM., SekiK., YoshiharaT., WatanabeN., OkumuraT., TajimaC., HuangS., KuoC. C.: Direct inhibition of pituitary LH secretion in rats by CB-154 (2-Br-α-ergocryptine).Endocrinology, 94: 911–914, 1974.
5.
StähelinH., Burckhardt-VischerB., FlückingerE.: Rat mammary cancer inhibition by a prolactin suppressor, 2-Bromo-α-ergokryptine (CB 154).Expe-rientia, 27: 915–916, 1971.
6.
YanaiR., NagasawaH.: Inhibition by ergocornine and 2-Br-α-ergocryptin of spontaneous mammary tumor appearance.Experientia,27: 934, 1971.
